Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

BACKGROUNDS/AIM: Sodium glucose co-transporter 2 inhibitors promote osmotic/natriuretic diuresis and reduce excess fluid volume, and this improves cardiovascular outcomes, including hospitalization for heart failure. We sought to assess the effect of empagliflozin on estimated fluid volumes in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shimabukuro, Michio, Teragawa, Hiroki, Okada, Yosuke, Takamura, Toshinari, Taguchi, Isao, Toyoda, Shigeru, Tomiyama, Hirofumi, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237440/
https://www.ncbi.nlm.nih.gov/pubmed/34183012
http://dx.doi.org/10.1186/s12933-021-01295-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237440/
https://www.ncbi.nlm.nih.gov/pubmed/34183012
http://dx.doi.org/10.1186/s12933-021-01295-6

Ejemplares similares